Publications
Detailed Information
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shaw, Alice T. | - |
dc.contributor.author | Yeap, Beow Y. | - |
dc.contributor.author | Solomon, Benjamin J. | - |
dc.contributor.author | Riely, Gregory J. | - |
dc.contributor.author | Gainor, Justin | - |
dc.contributor.author | Engelman, Jeffrey A. | - |
dc.contributor.author | Shapiro, Geoffrey I. | - |
dc.contributor.author | Costa, Daniel B. | - |
dc.contributor.author | Ou, Sai-Hong I. | - |
dc.contributor.author | Butaney, Mohit | - |
dc.contributor.author | Salgia, Ravi | - |
dc.contributor.author | Maki, Robert G. | - |
dc.contributor.author | Varella-Garcia, Marileila | - |
dc.contributor.author | Doebele, Robert C. | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Kulig, Kimary | - |
dc.contributor.author | Selaru, Paulina | - |
dc.contributor.author | Tang, Yiyun | - |
dc.contributor.author | Wilner, Keith D. | - |
dc.contributor.author | Kwak, Eunice L. | - |
dc.contributor.author | Clark, Jeffrey W. | - |
dc.contributor.author | Iafrate, A. John | - |
dc.contributor.author | Camidge, D. Ross | - |
dc.date.accessioned | 2022-04-18T09:24:31Z | - |
dc.date.available | 2022-04-18T09:24:31Z | - |
dc.date.created | 2021-10-21 | - |
dc.date.issued | 2011-10 | - |
dc.identifier.citation | The Lancet Oncology, Vol.12 No.11, pp.1004-1012 | - |
dc.identifier.issn | 1470-2045 | - |
dc.identifier.other | 145277 | - |
dc.identifier.uri | https://hdl.handle.net/10371/178107 | - |
dc.description.abstract | Background ALK gene rearrangement defines a new molecular subtype of non-small-cell lung cancer (NSCLC). In a recent phase 1 clinical trial, the ALK tyrosine-kinase inhibitor (TKI) crizotinib showed marked antitumour activity in patients with advanced, ALK-positive NSCLC. To assess whether crizotinib affects overall survival in these patients, we did a retrospective study comparing survival outcomes in crizotinib-treated patients in the trial and crizotinib-naive controls screened during the same time period. Methods We examined overall survival in patients with advanced, ALK-positive NSCLC who enrolled in the phase 1 clinical trial of crizotinib, focusing on the cohort of 82 patients who had enrolled through Feb 10, 2010. For comparators, we identified 36 ALK-positive patients from trial sites who were not given crizotinib (ALK-positive controls), 67 patients without ALK rearrangement but positive for EGFR mutation, and 253 wild-type patients lacking either ALK rearrangement or EGFR mutation. To assess differences in overall survival, we assessed subsets of clinically comparable ALK-positive and ALK-negative patients. Findings Among 82 ALK-positive patients who were given crizotinib, median overall survival from initiation of crizotinib has not been reached (95% CI 17 months to not reached); 1-year overall survival was 74% (95% CI 63-82), and 2-year overall survival was 54% (40-66). Overall survival did not differ based on age, sex, smoking history, or ethnic origin. Survival in 30 ALK-positive patients who were given crizotinib in the second-line or third-line setting was significantly longer than in 23 ALK-positive controls given any second-line therapy (median overall survival not reached [95% CI 14 months to not reached] vs 6 months [4-17], 1-year overall survival 70% [95% CI 50-83] vs 44% [23-64], and 2-year overall survival 55% [33-72] vs 12% [2-30]; hazard ratio 0.36, 95% CI 0.17-0.75; p=0.004). Survival in 56 crizotinib-treated, ALK-positive patients was similar to that in 63 ALK-negative, EGFR-positive patients given EGFR TKI therapy (median overall survival not reached [95% CI 17 months to not reached] vs 24 months [15-34], 1-year overall survival 71% [95% CI 58-81] vs 74% [61-83], and 2-year overall survival 57% [40-71] vs 52% [38-65]; p=0.786), whereas survival in 36 crizotinib-naive, ALK-positive controls was similar to that in 253 wild-type controls (median overall survival 20 months [95% CI 13-26] vs 15 months [13-17]; p=0.244). Interpretation In patients with advanced, ALK-positive NSCLC, crizotinib therapy is associated with improved survival compared with that of crizotinib-naive controls. ALK rearrangement is not a favourable prognostic factor in advanced NSCLC. Funding Pfizer Inc, V Foundation for Cancer Research. | - |
dc.language | 영어 | - |
dc.publisher | The Lancet Publishing Group | - |
dc.title | Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1016/S1470-2045(11)70232-7 | - |
dc.citation.journaltitle | The Lancet Oncology | - |
dc.identifier.wosid | 000295885200020 | - |
dc.identifier.scopusid | 2-s2.0-80053386829 | - |
dc.citation.endpage | 1012 | - |
dc.citation.number | 11 | - |
dc.citation.startpage | 1004 | - |
dc.citation.volume | 12 | - |
dc.identifier.sci | 000295885200020 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | EML4-ALK FUSION GENE | - |
dc.subject.keywordPlus | INFLAMMATORY MYOFIBROBLASTIC TUMOR | - |
dc.subject.keywordPlus | ANAPLASTIC LYMPHOMA KINASE | - |
dc.subject.keywordPlus | ACTIVATING MUTATIONS | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | NEUROBLASTOMA | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | GEFITINIB | - |
dc.subject.keywordPlus | 2P23 | - |
dc.subject.keywordPlus | EGFR | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.